Lymphocyte targeted IL-15 Delivery Engineering Services
Creative Biolabs provides advanced molecular engineering solutions to overcome the limitations of systemic cytokine delivery. We specialize in designing custom IL-15 fusion proteins, superagonists, and nanoconstructs that ensure targeted activation of cytotoxic lymphocytes while rigorously mitigating systemic toxicity and enhancing pharmacokinetics. Clients receive fully validated, high-purity protein leads accompanied by comprehensive in vitro functional data and preliminary preclinical data packages suitable for next-stage research and regulatory submission preparation.
Introduction What We Can Offer How We Can Help Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Engineered IL-15 for Targeted Lymphocyte Activation
Interleukin-15 (IL-15) is a powerful γ-chain cytokine that drives the proliferation and activation of cytotoxic T cells and NK cells, making it crucial for next-generation immunomodulatory research. However, its short plasma half-life and non-specific binding cause severe, dose-limiting systemic toxicity. Cited literature confirms that engineering IL-15 into targeted complexes - such as immunocytokines or nanodelivery platforms - is essential to separate efficacy from toxicity and enhance activity through mechanisms like multivalent transpresentation. Creative Biolabs' platform is built upon this core principle: precision targeting for superior outcomes.
For an in-depth analysis of how our services can be tailored to your specific project needs, request a consultation.
Fig.1 Cytotoxic innate lymphoid cells sense tumor-derived IL-15. 1
What We Can Offer
Customized Molecular Blueprinting
End-to-end rational design of IL-15 complexes, including proprietary superagonist muteins, selective non-signaling IL-15Rα subunits, and flexible fusion topologies, all tailored to your specific tumor antigen or therapeutic goal.
Validated Toxicity Mitigation
Integration of 'blind' activation or conditional cleavage systems to minimize systemic cytokine exposure, drastically widening the therapeutic window and de-risking preclinical translation.
Rigorous Functional Specificity Testing
Comprehensive in vitro validation protocols to confirm preferential activation of effector cells (CD8+ T cells, NK cells) while rigorously assessing and eliminating off-target T-regulatory cell (Treg) expansion.
Lymphocyte targeted IL-15 Delivery Engineering Services at Creative Biolabs
We design and validate fusion proteins that link the high-potency IL-15 superagonist to anti-PD-1 or anti-PD-L1 antibodies. This creates a strategic payload that simultaneously blocks the checkpoint signal and provides targeted, localized growth support to effector cells that infiltrate the TME.
Why Choose Us?
|
Core Advantages
|
Unique Features
|
|
Treg-Sparing Advantage
|
We exploit IL-15's natural characteristic of supporting CD8+ T cells and NK cells while suppressing Treg expansion. Our designs maximize this inherent advantage by incorporating muteins that further de-favor unwanted cell populations.
|
|
Multivalent & Transpresentation Mimicry
|
We utilize multivalent display on nanoscale platforms and sophisticated fusion constructs to mimic the natural transpresentation of IL-15/IL-15Rα, achieving high local avidity and specific signal delivery to target lymphocytes, a key differentiator for enhanced efficacy.
|
|
Systemic Toxicity Mitigation
|
By employing our 'blind' activation and TME-targeting strategies, we have successfully mitigated systemic side effects common in non-targeted IL-15, thereby significantly widening the therapeutic window.
|
To fully understand the Creative Biolabs advantage, we invite you to get a quote today.
Customer Reviews
-
Exceptional Specificity Control
Using Creative Biolabs' services in our research has significantly improved the specificity of T cell proliferation. Their blind mutein technology allowed us to precisely restrict IL-15 signaling to T cells that also expressed our target antigen, solving the systemic Treg expansion issue we had with their competitor's IL-2 fusions. -Dr. L**zo.
-
Unprecedented PK Improvement
Creative Biolabs' services facilitated the successful incorporation of an albumin-binding domain, resulting in a stable fusion protein with an eight-fold increase in serum half-life. The consistency and detail in their functional data were crucial for justifying our reduced dosing schedule in the subsequent animal study. - Dr. Ka**e.
FAQs
Q:
How do Creative Biolabs' targeted IL-15 solutions compare to standard recombinant rhIL-15?
A:
Standard rhIL-15 suffers from systemic toxicity and rapid clearance. Our targeted solutions, such as immunocytokines, exhibit significantly reduced systemic activity. They also boast a vastly improved pharmacokinetic profile, allowing for lower and less frequent dosing while achieving superior anti-tumor potency.
Q:
What is the primary mechanism Creative Biolabs uses to mitigate systemic toxicity?
A:
We use a dual-pronged approach. First, we employ molecular shielding to limit activation in the systemic circulation. Second, we integrate a targeting moiety that physically concentrates the active payload at the tumor site or on tumor-infiltrating lymphocytes, minimizing exposure to sensitive off-target organs.
Related Services
Preclinical Testing
Leveraging our network of specialized facilities, we design and execute comprehensive, regulatory-compliant toxicology programs (acute, sub-chronic, and chronic) using a wide range of animal models (e.g., syngeneic, humanized).
Learn More →
Tumor-Targeted IL-15 Delivery Engineering
Focuses on developing suitable delivery vehicles for the final IL-15 complex to optimize stability, homogeneity, and in vitro release kinetics, ensuring a robust research product that minimizes aggregation and maintains activity during storage and administration.
Learn More →
How to Contact Us
Creative Biolabs provides the precision required to overcome the critical toxicity and half-life limitations that have constrained IL-15 therapeutics. To learn more about how our services can protect your research and to get a personalized project quote, please contact us.
Reference
-
Franz, Tobias et al. "Cytotoxic innate lymphoid cells sense tumor-derived IL-15: a novel mechanism of cancer immunosurveillance." Signal transduction and targeted therapy vol. 7,1 326. 17 Sep. 2022. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41392-022-01173-x
For Research Use Only | Not For Clinical Use
